﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Pain Medicine Palliative Medicine</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Pain Medicine Palliative Medicine"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.09.26362449v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.08.26362323v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.09.08.26362416v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.31.26361793v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.26.26359760v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.22.26361094v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.20.26360943v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.14.26360457v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.13.26360409v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.13.26360364v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.07.26359966v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.07.26359945v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.06.26359876v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.05.26359702v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.04.26359660v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.08.03.26359604v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.31.26359372v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.24.26357716v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.24.26358500v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.22.26358710v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.22.26358645v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.12.26356929v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.11.26357570v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.08.26357000v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.01.26356632v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.02.26356879v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.01.26356998v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.15.26355697v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.23.26356401v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.21.26356167v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.09.26362449v1?rss=1">
<title>
<![CDATA[
Multimodal hypersensitivity across the menarcheal transition is associated with pelvic pain in adolescents: a longitudinal study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.09.26362449v1?rss=1
</link>
<description><![CDATA[
Multimodal hypersensitivity (MMH), heightened sensitivity across multiple sensory modalities, is associated with chronic pain risk in adults. How MMH develops across adolescence and whether early pain experiences shape its trajectory remains unknown. The Early Menstrual Pain Impact on Multisensory Hypersensitivity (EMPATHY) study followed 300 premenarcheal adolescents (age M=11.29, SD=0.98 years) across the menarcheal transition with three visits comprising a comprehensive multimodal sensory testing battery: visual and auditory unpleasantness, a non-invasive bladder filling task, pressure pain thresholds, after-pain ratings, cold pain, and conditioned pain modulation. A principal component (PC) analysis of 24 baseline measures (n=214) identified three components accounting for 34.2% of variance: MMH (PC1; 16.5% of variance), a pressure-pain stimulus-response function (PC2; 9.3%), and bladder hypersensitivity (PC3; 8.4%). All experimental measures, and four self-report sensory sensitivity questionnaires projected as supplementary variables, loaded onto PC1, supporting its interpretation as MMH and replicating the component structure previously observed in adult women. Longitudinal trajectories of MMH (n=140) were modeled with linear mixed-effects regression with menstrual pain, pelvic pain, time, and their interactions as predictors, adjusting for pubertal staging. MMH decreased across the menarcheal transition (p=0.029). Pelvic pain (p=1.24x10-6), but not menstrual pain (p=0.205), was positively associated with MMH, independent of time and pubertal development. These findings establish MMH as a measurable, replicable sensory phenotype in early adolescence that covaries with non-menstrual pelvic pain, and position it as a candidate early marker of nociplastic pain risk. Future studies are needed to support interventions and screening for elevated sensory sensitivity before pain becomes clinically entrenched.
]]></description>
<dc:creator><![CDATA[ Kmiecik, M. J., Hellman, K. M., Darnell, S. E., Miller, G. E., Tu, F. F. ]]></dc:creator>
<dc:date>2026-09-11</dc:date>
<dc:identifier>doi:10.64898/2026.09.09.26362449</dc:identifier>
<dc:title><![CDATA[Multimodal hypersensitivity across the menarcheal transition is associated with pelvic pain in adolescents: a longitudinal study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-11</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.08.26362323v1?rss=1">
<title>
<![CDATA[
Dysregulation of microRNAs in fibromyalgia: potential as biomarkers and disorder modulators 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.08.26362323v1?rss=1
</link>
<description><![CDATA[
Fibromyalgia syndrome (FMS) is characterized by chronic widespread pain, fatigue and cognitive difficulties, but its underlying mechanisms remain incompletely understood. The uncertainty of the origins of FMS has hampered the development of treatments and diagnostic methods, and the available therapeutic options offer limited relief to patients, an estimated 2-4% of the population. The severe burden of FMS thus represents an urgent unmet clinical need.

MicroRNAs (miRNAs), non-coding short RNAs that have vital inhibitory roles in gene expression, have been explored in FMS pathophysiology. MicroRNA signatures associated with FMS may facilitate diagnosis and reveal new insights into the cellular and molecular mechanisms of FMS.

We compiled and analyzed publicly available data of dysregulated miRNAs in FMS. MiRNAs were categorized according to the direction of dysregulation (levels up or down in FMS vs health) and compared across studies. Only miRNAs identified as dysregulated in the same direction in at least two studies were included. RNA targets of at least two microRNAs were inferred using TargetScan and subjected to pathway enrichment analysis using Reactome, ShinyGo v.8, miRNA Tissue Atlas 2025 and EnrichR.

This analysis revealed enrichment in pathways central to cell signaling and immune function, such as regulation of PTEN, circadian rhythm and RNA metabolic processes. Additionally, the dysregulated miRNAs in FMS were over-represented in immune-related tissues such as lymph node and spleen.

Collectively, these findings support a role for immune dysregulation in FMS. By using an integrative approach, we identified candidate pathways and molecular targets that warrant further experimental validation.
]]></description>
<dc:creator><![CDATA[ Tamashiro-Orrego, A., Andersson, D., Martinez-Nunez, R. T. ]]></dc:creator>
<dc:date>2026-09-09</dc:date>
<dc:identifier>doi:10.64898/2026.09.08.26362323</dc:identifier>
<dc:title><![CDATA[Dysregulation of microRNAs in fibromyalgia: potential as biomarkers and disorder modulators]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.09.08.26362416v1?rss=1">
<title>
<![CDATA[
Childhood trauma, accelerated biological aging and chronic pain across two population cohorts 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.09.08.26362416v1?rss=1
</link>
<description><![CDATA[
BackgroundAdverse childhood experiences are associated with reduced healthy longevity, multimorbidity, and chronic pain, but the biological mechanisms involved remain poorly understood. Epigenetic age acceleration (EAA), a DNA methylation marker of biological aging, may represent a pathway through which early-life stress becomes embedded. We therefore examined associations between childhood trauma (CT), EAA and chronic pain, and investigated whether accelerated biological aging mediates the relationship between CT and chronic pain in women and men.

MethodsWe analysed two independent population cohorts from the UK and USA: Generation Scotland (n = 901) and MIDUS (n = 1041). EAA was derived from first-generation (Hannum and Horvath) and second-generation (GrimAge and PhenoAge) DNA methylation clocks relative to chronological age. DunedinPACE, a third-generation measure, was used to estimate pace of aging. Associations between CT, EAA and chronic pain were examined using sex-stratified regression models adjusted for confounders and covariates, followed by mediation analyses.

FindingsCT was associated with chronic pain and with accelerated biological aging measured primarily using second- and third-generation clocks. Associations were consistently stronger in women, and smoking-related methylation contributed substantially to the relationship between EAA and chronic pain. Mediation analyses revealed that EAA partially accounts for the link between CT and chronic pain in women.

InterpretationSecond- and third-generation clocks appeared more sensitive to the long-term consequences of childhood trauma than clocks trained primarily on chronological age. The findings suggest that CT contributes to chronic pain vulnerability partly through accelerated biological aging pathways, particularly in women.

FundingUK Research and Innovation, Lily, and Arthritis UK.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSAdverse childhood experiences are associated with increased risk of chronic pain, multimorbidity and premature mortality. DNA methylation-based epigenetic clocks are emerging biomarkers of biological aging and predictors of morbidity. Several studies have examined associations between childhood adversity and epigenetic age acceleration, but findings remain heterogeneous across cohorts, adversity measures and clock types. Chronic pain has also been linked to altered biological aging profiles. However, no previous study has integrated childhood trauma, biological aging and chronic pain within a unified analytical framework across multiple generations of epigenetic clocks. In addition, few studies have stratified by sex despite evidence that women exhibit greater chronic pain burden and multimorbidity across the lifespan.

Added value of this studyUsing two independent population cohorts from the UK and USA, we demonstrate that childhood trauma is associated with both chronic pain and epigenetic age acceleration, with associations preferentially captured by second- and third-generation epigenetic clocks. These relationships were more consistent in women than men and were dose-dependent with trauma severity. Furthermore, epigenetic age acceleration established using GrimAge clocks, partially mediates the relationship between childhood trauma and chronic pain in women. Sequential adjustment models and sensitivity analyses additionally demonstrated that smoking-related biological aging pathways contribute substantially to these relationships, particularly in women.

Implications of all the available evidenceThese findings support the hypothesis that childhood trauma contributes to chronic pain vulnerability partly through accelerated biological aging. The preferential involvement of second-generation epigenetic clocks suggests that morbidity-related aging measures capture the long-term biological consequences of early-life adversity more sensitively than chronological age predictors. The stratified analyses indicate that biological embedding of childhood trauma likely differs between women and men and may contribute to sex-specific trajectories of morbidity. Additional studies are required to determine whether accelerated biological aging following childhood trauma is modifiable through behavioural, clinical, or public health interventions.
]]></description>
<dc:creator><![CDATA[ Russell, H., Singleton, S., Colvin, L., Macfarlane, G., Cole, S., Bell, C. G., Hales, T. G. ]]></dc:creator>
<dc:date>2026-09-09</dc:date>
<dc:identifier>doi:10.64898/2026.09.08.26362416</dc:identifier>
<dc:title><![CDATA[Childhood trauma, accelerated biological aging and chronic pain across two population cohorts]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.31.26361793v1?rss=1">
<title>
<![CDATA[
The effect of high-dose glucocorticoids on opioid consumption in the first 24 hours after elective hip and knee arthroplasty: A natural experiment study of 47,317 surgeries in Eastern Denmark 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.31.26361793v1?rss=1
</link>
<description><![CDATA[
BackgroundIn Denmark, perioperative high-dose glucocorticoid treatment were step-wisely implemented for total hip arthroplasty (THA), total knee arthroplasty (TKA), and unicompartmental knee arthroplasty (UKA). We aimed to estimate the effect of a single high dose of glucocorticoids on opioid consumption following primary THA, TKA, and UKA.

MethodsThis was a prespecified analysis of a multicenter natural experiment using electronic health record data. We included elective THA, TKA, or UKA surgeries performed in Eastern Denmark from 2017-2025. At each center, surgeries before implementation of high-dose glucocorticoids served as controls, whereas surgeries after implementation comprised the intervention group. The primary outcome was the between-group difference in cumulative 0-24h opioid consumption, which included preemptive end-of-surgery doses. The predefined minimal important difference was set at 5 mg IV morphine equivalents. Secondary outcomes were maximum 0-10 numerical rating scale (NRS) pain score and incidence of opioid-related adverse events within 24 hours, hospital length of stay, and days alive and out of hospital at 30 days.

ResultsA total of 47,317 surgeries performed at nine centers were analyzed: 13,010 controls and 34,307 in the intervention group. During the study period, five centers implemented high-dose glucocorticoids for THA patients, two for TKA/UKA patients. High-dose glucocorticoids were administered to 6% of patients before implementation versus 92% after. High-dose glucocorticoids resulted in a mean reduction of 3.8 mg intravenous (IV) morphine equivalents (95% CI 3.3;4.3). The intervention also reduced the maximum 0-24h NRS pain score by 0.8 points (99% CI 0.7;0.9), but there was no difference in adverse events, length of stay, or days alive and out of hospital.

ConclusionsImplementation of high-dose glucocorticoids reduced 0-24-hour opioid consumption by 3.8 mg IV morphine equivalents after elective hip and knee arthroplasty. This difference was below the prespecified minimal important difference threshold.

Online registrationhttps://doi.org/10.1101/2025.11.11.25339982
]]></description>
<dc:creator><![CDATA[ Laigaard, J., Moeller, M. O., Olsen, M. H., Overgaard, S., Mathiesen, O., Karlsen, A. P. H. ]]></dc:creator>
<dc:date>2026-09-02</dc:date>
<dc:identifier>doi:10.64898/2026.08.31.26361793</dc:identifier>
<dc:title><![CDATA[The effect of high-dose glucocorticoids on opioid consumption in the first 24 hours after elective hip and knee arthroplasty: A natural experiment study of 47,317 surgeries in Eastern Denmark]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-09-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.26.26359760v1?rss=1">
<title>
<![CDATA[
Pain state-dependent multimodal assessment in non-specific low back pain: a pseudorandomized study design with implementation insights 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.26.26359760v1?rss=1
</link>
<description><![CDATA[
BackgroundFluctuations in pain intensity are intrinsic to non-specific chronic low back pain (nsCLBP). Nevertheless, pain fluctuations have rarely been considered when investigating pathophysiological mechanisms. Therefore, a novel study protocol was developed and implemented to systematically assess the impact of fluctuating pain states on pain-related measures.

MethodsThe final study cohort consisted of 45 nsCLBP patients and 47 age- and sex-matched healthy controls (HCs). Patients participated in three visits, conducted during different pain states (i.e. clinically relevant pain, low-intensity clinical pain / pain-free, clinically irrelevant pain induced using a Qutenza 8% capsaicin patch). Pain fluctuations were monitored through online assessments every four days and guided the pseudorandomized visit scheduling. HCs participated in a single visit. Each study visit comprised a multimodal battery of pain-related measures.

Results93.33% of patients completed all three visit types in a pseudorandomized order ({chi}{superscript 2}=1.50, p=0.826). Visit scheduling was possible due to the high self-report adherence (median=93.48%), unrelated to self-report burden ({rho}=-0.097, p=0.53). Study visits were conducted during different pain states, as indicated by: i) the significantly higher low back pain intensity in the clinically relevant pain visit (mean[SD]: 3.98[0.90]), compared to the low-intensity clinical pain (1.03[0.86]) and clinically irrelevant pain (1.13[0.82]) visits (p-values<0.001), as well as by ii) the successful induction of a moderate-to-high clinically irrelevant pain across assessments.

ConclusionDespite scheduling complexity and pain state transition uncertainty, a pain state-dependent pseudorandomized study design is feasible and could improve the understanding of nsCLBP mechanisms.
]]></description>
<dc:creator><![CDATA[ Chozas Barrientos, B., Hau, M., Sirucek, L., Langenfeld, A., Wehrli, M., Wirth, B., Zoelch, N., Devan, J., Dudli, S., Schweinhardt, P. ]]></dc:creator>
<dc:date>2026-08-31</dc:date>
<dc:identifier>doi:10.64898/2026.08.26.26359760</dc:identifier>
<dc:title><![CDATA[Pain state-dependent multimodal assessment in non-specific low back pain: a pseudorandomized study design with implementation insights]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-31</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.22.26361094v1?rss=1">
<title>
<![CDATA[
Evaluating cranial electrotherapy stimulation for anxiety associated with breathlessness in palliative care: a mixed-methods feasibility study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.22.26361094v1?rss=1
</link>
<description><![CDATA[
ObjectivesTo explore the acceptability and tolerability of cranial electrotherapy stimulation (CES) using Alpha-Stim AID as a potential intervention for anxiety associated with breathlessness in people with advanced chronic respiratory disease.

MethodsA multicentre, mixed-methods, non-randomised interventional feasibility study with a parallel usual-care control group. Participants were adults with chronic respiratory disease and significant anxiety and breathlessness symptoms (assessed via Integrated Palliative Outcome Scale) receiving care from hospice services. The intervention groups used Alpha-Stim AID for eight weeks either at a fixed or personalised dose, followed by a four-week follow-up period. This feasibility study was not powered to assess clinical efficacy.

Results12.5% of screened patients at the primary site were eligible, and 29 unique participants were recruited. Three participants withdrew from the study (10.3%), none of which were attributable to CES. Most adverse events were mild, with headache reported frequently across control and intervention groups. Outcome measure completion was high, with data missingness below 6.4%. Numerical rating scales of anxiety and breathlessness fluctuated daily and remained broadly static, whereas GAD-7 scores assessing anxiety improved over time across all groups. This feasibility study was not powered to assess clinical efficacy.

ConclusionCES using Alpha-Stim AID was deliverable within hospice services and was generally acceptable and tolerable among participants who enrolled. Our findings support further evaluation which should involve a fully-powered randomised controlled trial against a sham device to determine whether CES provides clinically meaningful improvements in anxiety for this patient population.

What is already known on this topicO_LIAnxiety is common amongst patients with chronic respiratory diseases, such as COPD and interstitial lung disease. Management is primarily non-pharmacological.
C_LIO_LICranial electrotherapy stimulation is used for treatment of anxiety related to primary anxiety disorders, such as generalised anxiety disorder.
C_LIO_LINo studies have been carried out exploring cranial electrotherapy stimulation in a palliative care population.
C_LI

What this study addsO_LICranial electrotherapy stimulation using Alpha-Stim AID was deliverable within hospice services. The intervention was generally accepted and tolerable amongst enrolled participants.
C_LIO_LIHeadache was common across all three groups. Dizziness was more commonly reported in the personalised dose group.
C_LI

How this study might affect research, practice or policyO_LIOur findings support the future development of a definitive randomised controlled trial against a sham device to determine whether CES has a clinically meaningful effect for anxiety in this patient group.
C_LI
]]></description>
<dc:creator><![CDATA[ Bleazard, L., Copping, S. R., Booth, S., Gray, L. J., Faull, C., Walker, K., Griffiths, C., Wenzel, D. ]]></dc:creator>
<dc:date>2026-08-25</dc:date>
<dc:identifier>doi:10.64898/2026.08.22.26361094</dc:identifier>
<dc:title><![CDATA[Evaluating cranial electrotherapy stimulation for anxiety associated with breathlessness in palliative care: a mixed-methods feasibility study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.20.26360943v1?rss=1">
<title>
<![CDATA[
Longitudinal Characterization of Nociplastic Pain in Systemic Lupus Erythematosus: A Nationwide Registry Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.20.26360943v1?rss=1
</link>
<description><![CDATA[
BackgroundNociplasticity is common in systemic lupus erythematosus (SLE), yet its longitudinal trajectory remain poorly characterized.

MethodsPatients with SLE in the FORWARD Databank were classified as Minimal, Type 1, Type 2, or Mixed using the Polysymptomatic Distress Scale (PSD[&ge;]8) and the Systemic Lupus Activity Questionnaire (SLAQ) inflammatory domain score ([&ge;]2). Cross-sectional analyses (N=372) compared pain, function, disability, depression, organ damage, and medication use. Longitudinal analyses (n=301; median 3.7 years) characterized phenotype transitions using continuous-time Markov models and identified latent trajectory subgroups using joint group-based trajectory modeling (GBTM).

FindingsAt baseline, 29% were Minimal, 12% Type 1, 13% Type 2, and 47% Mixed. Functional impairment increased stepwise: SF-36 PCS worsened from 49.7 in Minimal to 30.0 in Mixed; PROMIS Pain Interference from 46.2 to 63.6 (both p<0.001). BILD organ damage was highest in Mixed (3.9 vs 2.6-2.9; p<0.001). Depression rose from 3% to 43% and opioid use reached 44% in Mixed. Longitudinally, Minimal and Mixed were persistent (mean duration 2.0 and 1.8 years; one-year retention 70%), while Type 1 and Type 2 were transient ([~]0.5 years; retention 18% and 28%). Exit trajectories were asymmetric: Type 1 moved preferentially to Minimal (49% of exits), whereas Type 2 moved to Mixed (65%; p<0.001). Population-average PSD was nearly flat (+0.014 SD/year, p=0.07); opioid use declined to near zero in Minimal and Type 1 but remained high in Type 2 and Mixed. Joint GBTM identified four severity classes along a Minimal-to-Mixed diagonal, indicating that the two axes scale together longitudinally and that pure Type 1 and Type 2 are transient.

InterpretationNociplastic phenotypes in SLE are persistent, severity-stratified, and associated with functional impairment, depression, cumulative damage, and sustained opioid burden. Type 1 and Type 2 are transient states with divergent exits: the former resolving, the latter progressing.

FundingLupus Research Alliance

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThe Type 1 and Type 2 systemic lupus erythematosus (SLE) framework distinguishes inflammatory manifestations from symptoms associated with nociplastic pain and has provided a clinically meaningful approach to understanding the heterogeneity of SLE. Patient-reported instruments, including the polysymptomatic distress (PSD) scale combined with inflammatory symptom assessment, have enabled classification of these phenotypes in both research and clinical settings. A search of PubMed, Embase, and Web of Science (from database inception to June 01, 2026) using the terms "systemic lupus erythematosus", "Type 1 SLE", "Type 2 SLE", "nociplastic pain", "nociplasticity", "polysymptomatic distress", "trajectory", and "transition", together with screening of reference lists of relevant articles, identified studies describing cross-sectional phenotype distributions, intermittent and persistent Type 2 symptoms, and molecular differences between phenotypes. However, whether Type 1 and Type 2 phenotypes represent stable disease states or transient manifestations of a patients underlying longitudinal symptom trajectory is unknown.

Added value of this studyThis study analyzed prospectively collected patient-reported data from 301 SLE patients enrolled in the nationwide FORWARD registry over a median follow-up of 3.7 years to characterize the longitudinal behavior of Type 1 and Type 2 phenotypes. By combining continuous-time Markov modelling with group-based trajectory modelling, we distinguished threshold-defined phenotype transitions from underlying symptom trajectories. We found that Minimal and Mixed phenotypes were highly stable over time, whereas Type 1 and Type 2 phenotypes represented transient states with distinct transition patterns. Data-driven trajectories formed a stable severity continuum from Minimal to Mixed rather than persistent Type 1 and Type 2 classes. Higher nociplastic burden was also associated with sustained impairment in physical function, depression, medication burden, and opioid use.

Implication of all the available evidenceThese findings suggest that nociplastic symptom burden represents a persistent and clinically important component of SLE that is not fully captured by inflammatory disease activity alone. Routine assessment of nociplastic symptoms alongside inflammatory activity could improve longitudinal patient stratification and identify individuals who may benefit from combined immunomodulatory and symptom-directed management. Future studies should determine whether phenotype-informed treatment strategies improve long-term patient outcomes.
]]></description>
<dc:creator><![CDATA[ Huang, C.-Y., Tanguay-Sabourin, C., Liu, Y., Pedro, S., Dildine, T. C., Bozkurt, S., Katz, P., Michaud, K., Falasinnu, T. ]]></dc:creator>
<dc:date>2026-08-23</dc:date>
<dc:identifier>doi:10.64898/2026.08.20.26360943</dc:identifier>
<dc:title><![CDATA[Longitudinal Characterization of Nociplastic Pain in Systemic Lupus Erythematosus: A Nationwide Registry Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.14.26360457v1?rss=1">
<title>
<![CDATA[
Pain and Pain Sensitivity Assessments in the Acute to Chronic Pain Signatures (A2CPS) Program 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.14.26360457v1?rss=1
</link>
<description><![CDATA[
The Acute to Chronic Pain Signatures (A2CPS) project is a large, multisite, longitudinal observational study designed to identify biomarkers that predict the transition from acute to chronic pain following surgery in more than 2200 patients. Two participant cohorts were recruited before undergoing either knee arthroplasty or thoracic surgery. A unique feature of this study is its comprehensive evaluation of pain, including evoked and recall pain measures collected at baseline, 6-weeks, and 3-months following surgery, in addition to the primary pain outcome assessed remotely at 6 months. This paper describes the acquisition, quality control procedures, and available pain and pain sensitivity variables included in the A2CPS study. Self-report pain assessments include surgical site (i.e., index) pain intensity, pain interference and quality, spatial distribution of pain using body maps, and pain-related dysfunction specific to each cohort. Quantitative sensory testing yielded evoked pain sensitivity data including pressure pain thresholds, temporal summation of pain, dynamic mechanical allodynia, and conditioned pain modulation at both index and common sites across cohorts. Movement-evoked pain was assessed for each cohort using relevant functional tasks (knee: 10m walk and five-time-sit-to-stand tests, thoracic: deep breathing and coughing). Using baseline data from release v2.1.0, comprising approximately 1,400 participants, we evaluated interrelationships among pain variables. Overall, the A2CPS pain and pain sensitivity data provide a robust, comprehensive set of variables that supports the studys goal of uncovering predictive biomarkers of post-operative chronic pain and enables broader exploration relative to other study outcomes, including imaging, psychosocial, and "omics" data.
]]></description>
<dc:creator><![CDATA[ Frey-Law, L. A., Berardi, G., Ansari, B., Liu, Y., Satpathy-Horton, B., Sluka, K. A., Vance, C. G., Dailey, D. L., McCarthy, R. J., Wager, T. D., Lindquist, M. A., Harte, S. E., the A2CPS Consortium ]]></dc:creator>
<dc:date>2026-08-19</dc:date>
<dc:identifier>doi:10.64898/2026.08.14.26360457</dc:identifier>
<dc:title><![CDATA[Pain and Pain Sensitivity Assessments in the Acute to Chronic Pain Signatures (A2CPS) Program]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-19</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.13.26360409v1?rss=1">
<title>
<![CDATA[
Pain on the Street: Implementation of a Field-Based Pain Response for People Experiencing Homelessness 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.13.26360409v1?rss=1
</link>
<description><![CDATA[
2.BackgroundHomeless individuals are disproportionately affected by limited access to primary care and pain management services. While community-based organizations frequently conduct outreach, few have ethical, standardized, or replicable methods for assessing pain and distributing referrals in field settings. Existing models range from passive, meals-only outreach, to costly mobile clinics with limited reach. This leaves a critical gap that a low-resource, agile framework is designed to address.

ObjectiveThe aim of this quality-improvement initiative was to implement and iteratively refine a standardized, field-based pain assessment and response pathway for adults experiencing homelessness and to evaluate its feasibility, fidelity, safety, and operational barriers during routine outreach.

MethodsA cross-sectional quality improvement needs assessment was conducted during homeless outreach activities in San Francisco and Sacramento using convenience sampling. The intervention framework incorporated volunteer training, cognitive capacity screening, verbal informed consent, vital sign collection, and predefined criteria for emergency escalation. Participants were unsheltered adults with adequate decisional capacity to provide voluntary informed consent.

ResultsThe dataset included 193 encounters, with valid pain scores for 175 participants. Mean pain was 3.79 {+/-} 2.78, with a median of 3. Cold packs were used for acute discomfort and foot or ankle pain, while hot packs were used for joint pain. Some participants declined comfort measures. No supply shortages, referral confusion, or emergency-escalation delays were documented. Telephone access remained a barrier to referral completion.

ConclusionThis framework demonstrates a replicable and ethically grounded model for field-based pain assessment and referral during homeless outreach. The pathway was feasible and safe to implement, expanded care options beyond default emergency-department referral by directing stable nonemergent pain toward primary care, and identified limited telephone access as a major barrier to completing follow-up.
]]></description>
<dc:creator><![CDATA[ Valliant, S. J., Joseph, M., Sharma, M. S., Durosinmi, G. P., Fitts, D., Tran, S., Gonzalez, A. N., Kothari, S., Anderson, T., Ralh, R., Lee, A. K., Parton, S. S., Shirinzada, F., Kulik, C. ]]></dc:creator>
<dc:date>2026-08-20</dc:date>
<dc:identifier>doi:10.64898/2026.08.13.26360409</dc:identifier>
<dc:title><![CDATA[Pain on the Street: Implementation of a Field-Based Pain Response for People Experiencing Homelessness]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-20</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.13.26360364v1?rss=1">
<title>
<![CDATA[
The implementation of a falls observational tool and its clinical effectiveness of reducing falls in a palliative care setting: a mixed methods study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.13.26360364v1?rss=1
</link>
<description><![CDATA[
BackgroundFalls are a major safety concern in healthcare. In palliative care, patients are particularly vulnerable due to complex symptom burdens and rapid physical decline. However, standard falls risk assessment tools, primarily designed for acute clinical environments, rely on static risk scores and lack efficacy in hospice settings. The Falls Early Warning Score (FEWS) is a observational tool developed to address the specific contributing factors and complex needs of palliative patients.

AimsTo explore and understand staff views regarding the implementation, utility, and benefits of the FEWS tool to identify people at risk of falling in a specialist palliative care inpatient unit.

MethodsA mixed-methods study was conducted at a UK hospice. Healthcare professionals with clinical experience using the FEWS chart completed an electronic questionnaire assessing their confidence, practice, and perceived barriers. Questionnaire outcomes informed subsequent face-to-face, semi-structured interviews. Qualitative data were evaluated using reflexive thematic analysis.

ResultsEleven staff completed the questionnaire, and five participated in interviews. Three major themes were identified: (1) Education, highlighting staff preferences for 1:1 training and the necessity of dedicated user guides; (2) Location and format of the FEWS tool, contrasting the data collection benefits of electronic formats against the bedside accessibility of paper charts; and (3) Recognised benefits of the FEWS tool, including its ability to prompt safe staffing levels, highlight variable patient presentation, and mitigate the emotional and physical impact of falls.

ConclusionsIt is feasible and highly acceptable to integrate bespoke falls risk assessment tools into palliative care. By addressing the unique complexities of hospice patients, customised tools like FEWS can empower staff and support dynamic clinical decision-making. Further research is required to evaluate their clinical efficacy in reducing falls.

KEY MESSAGESO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIFalls are one of the most frequently recorded safety incidents in healthcare, and palliative care patients are at a high risk of falling due to fluctuating physical decline and complex symptom burdens.
C_LIO_LIStandard falls observational assessment tools are primarily designed for acute hospital settings and lack efficacy in hospice environments because they rely on fixed, static risk scores.
C_LI

What this study addsO_LIBespoke falls observational assessment tools (such as the FEWS chart) are highly acceptable to hospice staff and are perceived to improve falls management by prompting safe staffing levels and highlighting rapid patient deterioration.
C_LIO_LIThe successful implementation of new clinical tools in palliative care requires continuous, tailored educational support (e.g., 1:1 training and dedicated user guides) and careful consideration of bedside accessibility.
C_LI

How this study might affect research, practice or policyO_LIThe findings support the evidence base for developing and integrating customised falls management solutions into specialist palliative care clinical practice.
C_LIO_LIThis study highlights the need for future prospective research to determine the quantitative clinical effectiveness of the FEWS tool in reducing the actual incidence of falls.
C_LI
]]></description>
<dc:creator><![CDATA[ Parfitt, C., Kirk, E., Stanley, S., Nwosu, A. C. ]]></dc:creator>
<dc:date>2026-08-18</dc:date>
<dc:identifier>doi:10.64898/2026.08.13.26360364</dc:identifier>
<dc:title><![CDATA[The implementation of a falls observational tool and its clinical effectiveness of reducing falls in a palliative care setting: a mixed methods study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.07.26359966v1?rss=1">
<title>
<![CDATA[
Relevance Based Prediction: A Transparent, Non-Artificial Intelligence, Mathematical Solution to Personalized Opioid Treatment 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.07.26359966v1?rss=1
</link>
<description><![CDATA[
Accurate prediction of individual medical outcomes is essential for optimizing treatment allocation amid rising costs, coverage denials, and limited clinical resources. Traditional predictive models, including regression and neural networks, rely on average effects and cannot tailor predictions to the specific circumstances of individual cases. We present relevance-based prediction (RBP), a model-free method that predicts outcomes as weighted averages of observed cases, with weights determined by a rigorously defined measure of relevance. Unlike model-based methods that rely on fixed calibrated parameters, RBP revisits the original data for each prediction and customizes both the cases and variables used. Applied to opioid treatment, RBP provides case-specific insights unavailable from conventional models, including how each prior case informs a prediction, how each variable affects its reliability and value, and how reliable the prediction is before it is made. These individualized insights may prevent misleading average-based decisions and reduce harmful or suboptimal treatment.
]]></description>
<dc:creator><![CDATA[ Robinson, C. L., Turkington, D., Lee, L., Kritzman, M., Yong, R. J. ]]></dc:creator>
<dc:date>2026-08-10</dc:date>
<dc:identifier>doi:10.64898/2026.08.07.26359966</dc:identifier>
<dc:title><![CDATA[Relevance Based Prediction: A Transparent, Non-Artificial Intelligence, Mathematical Solution to Personalized Opioid Treatment]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.07.26359945v1?rss=1">
<title>
<![CDATA[
Targeted Pulsed Radio Frequency (PRF) Stimulation in the Management of Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Placebo-Controlled Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.07.26359945v1?rss=1
</link>
<description><![CDATA[
ObjectiveTo evaluate the clinical efficacy of non-invasive electrical pulsed radiofrequency (PRF) stimulation on diagnostic thresholds and subjective pain in chronic, pedal diabetic peripheral neuropathy (DPN).

MethodsA randomized, single-blind, placebo-controlled trial (ClinicalTrials.gov: NCT07725419) enrolled 92 patients with pedal DPN naive to PRF and scoring [&ge;] 4/10 on the Douleur Neuropathique 4 (DN4) test. Participants received either active PRF stimulation (n = 46) or a non-stimulating placebo (n = 46) applied bilaterally to the sciatic nerve in the popliteal fossa for 10 minutes per limb, once weekly for three weeks. The primary outcome was clinical neuropathic resolution (DN4 < 4). Secondary outcomes included subjective pain tracking via the Brief Pain Inventory-Short Form (BPI-SF) Worst Pain scale over a 6-month follow-up window.

Missing data were handled via Non-Responder Imputation (NRI). Longitudinal continuous trajectories were modeled using Linear Mixed-Effects Models (LMMs) adjusted for age, gender, and baseline medication use.

ResultsIn the Intention-to-Treat population (N = 92), a significant diagnostic responder effect occurred at 3 months, with 39.1% of active patients dropping below the diagnostic threshold for neuropathy (DN4 < 4) versus 19.6% of placebo controls (p = 0.039). For subjective pain, 47.7% of active patients achieved a Minimally Clinically Important Difference ([&ge;] 3-point reduction) in BPI Worst Pain at 1 month compared to 19.4% of placebo controls (p = 0.008). Multivariable logistic regression identified active treatment as a significant independent predictor of clinical response (Adjusted OR = 4.86; 95% CI: 1.56 to 17.53; p = 0.010). Continuous LMM tracking confirmed a statistically significant treatment-by-timepoint interaction for BPI Worst Pain at 1 month (p = 0.046).

ConclusionA brief, three-week course of non-invasive PRF stimulation serves as a safe, effective, non-pharmacological adjunct that aids in managing the diagnostic presentation of neuropathic pain and mitigates worst pain experiences in patients suffering from pedal DPN.
]]></description>
<dc:creator><![CDATA[ Linde, L. D., Berger, P. P., Landau, S. S., Libhaber, E., Potgieter, P., van Blerk, P., Birkill, C. F. ]]></dc:creator>
<dc:date>2026-08-10</dc:date>
<dc:identifier>doi:10.64898/2026.08.07.26359945</dc:identifier>
<dc:title><![CDATA[Targeted Pulsed Radio Frequency (PRF) Stimulation in the Management of Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Placebo-Controlled Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.06.26359876v1?rss=1">
<title>
<![CDATA[
Development of an interdisciplinary network to improve the capacity to conduct digital legacy research: a quality improvement initiative 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.06.26359876v1?rss=1
</link>
<description><![CDATA[
BackgroundDigital legacy (the digital information available about someone following their death) has increasing societal importance as personal assets and interactions become increasingly digitized. Healthcare professionals often have a limited understanding of how to address digital legacy in practice, and there is a lack of interdisciplinary networks to improve education, research, and professional development in digital legacy.

ObjectiveThis paper describes the development of an interdisciplinary initiative designed to build research capacity and develop consensus-based recommendations for integrating digital legacy into palliative care.

MethodOver 12-months, we conducted interdisciplinary engagement activities with diverse stakeholders, including clinicians, designers, and sociologists. We used a modified World Cafe method to facilitate dialogue and capture feedback on how memories are digitally curated, the management of digital estates, and intergenerational perspectives on digital legacy.

ResultsWe identified eight core recommendations for research and policy, including promoting digital legacy education, supporting policy development, and broadening the scope of interdisciplinary research. Our discussions highlighted the complexity of modern digital estates and the need for legal and ethical frameworks to protect individual rights.

ConclusionsThe Network demonstrates that interdisciplinary collaboratives can address important issues relating to digital legacy, which provides a foundation to conduct collaborative research that improves the management of digital legacies in society.
]]></description>
<dc:creator><![CDATA[ Nwosu, A. C., Tibbles, A., Goodwin, C., Kaye, L., Stanley, S. ]]></dc:creator>
<dc:date>2026-08-10</dc:date>
<dc:identifier>doi:10.64898/2026.08.06.26359876</dc:identifier>
<dc:title><![CDATA[Development of an interdisciplinary network to improve the capacity to conduct digital legacy research: a quality improvement initiative]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.05.26359702v1?rss=1">
<title>
<![CDATA[
Neural Alterations in Chronic Pain: MRI Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.05.26359702v1?rss=1
</link>
<description><![CDATA[
BackgroundChronic pain affects hundreds of millions worldwide and remains a major clinical challenge, despite numerous available treatments. Advances in brain imaging offer a promising path toward identifying neural signatures of chronic pain, potentially enhancing diagnosis and guiding treatment. However, while a core set of brain regions, including the insula, cingulate, and somatosensory cortices, has been repeatedly implicated, findings regarding other regions and connectivity patterns involved remain inconsistent, with limited robust replication.

ObjectiveTo address these gaps, the present work characterizes resting-state functional connectivity and gray matter volume differences between chronic pain patients and pain-free controls.

MethodsIn this secondary analysis of publicly available data, anatomical and resting-state functional MRI were analyzed from 56 patients with chronic knee pain due to osteoarthritis and 20 pain-free controls. Group comparisons used Network-Based Statistic (NBS) and Bayesian multivariate regression models, controlling for demographic covariates.

ResultsIn the pain group, about 75% of parcellated brain regions exhibited increased functional connectivity compared to controls. The 30 highest degree centrality regions in the NBS network were concentrated in regions consistent with prior pain neuroimaging findings. Additionally, chronic pain patients exhibited reduced gray matter volume (-3.98%; SD 1.2%) across 33% of parcellated brain regions, including key regions implicated in pain processing.

ConclusionsThese findings demonstrate widespread functional and anatomical neural alterations in chronic pain, revealing a global pattern of reorganization extending beyond previously reported network-pair effects. Characterizing such alterations may contribute to ongoing efforts to identify neuroimaging markers of chronic pain, with potential translational relevance.
]]></description>
<dc:creator><![CDATA[ Cohen-Blum, L., Eizman, S., Tetreault, P., Duek, O. ]]></dc:creator>
<dc:date>2026-08-07</dc:date>
<dc:identifier>doi:10.64898/2026.08.05.26359702</dc:identifier>
<dc:title><![CDATA[Neural Alterations in Chronic Pain: MRI Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.04.26359660v1?rss=1">
<title>
<![CDATA[
Biobehavioral pain profiling of minoritized adults with chronic widespread pain and clinical obesity before and after bariatric surgery: study protocol for a longitudinal, observational cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.04.26359660v1?rss=1
</link>
<description><![CDATA[
Chronic widespread pain (CWP) is highly prevalent among minoritized adults with clinical obesity, and symptom management is challenging. Weight loss via bariatric surgery is often recommended to improve musculoskeletal pain. However, there is significant variation in pain trajectories following bariatric surgery, and the impact of weight loss on movement-evoked pain is largely unknown. The current study aims to systematically characterize and quantify longitudinal changes in pain at rest and movement-evoked pain up to 6 months post-surgery, and to determine whether pain modulatory mechanisms, joint motion, and mechanical loading biosignatures mediate the relationship between weight loss and pain change. This study protocol details the research methodologies and procedures for a prospective observational cohort study of 60 individuals undergoing bariatric surgery for weight loss. Participants will complete questionnaires, anthropometric measurements, clinical and experimental pain testing, functional testing, and a standardized movement testing battery to assess joint motion and mechanical loading using camera-based motion capture before and at 3 and 6 months post- bariatric surgery. Generalized linear mixed models to assess the significance of changes in PAR, MEP, and all patient-reported outcome measures. Reduced models will treat the main effect of time as a fixed factor, and intra-individual repeated measures as random effects. Ethics and dissemination: This study protocol has been registered as an observational study with ClinicalTrials.gov (NCT0675386), version #1, in the United States and has been approved by the NYU Langone Health Institutional Review Board (IRB#: i21-01652) and the New York City Health + Hospitals/Bellevue Research Office (Bellevue Study ID #: STUDY00003739). Study results will be published in peer-reviewed journals and presented at national and international conferences and community events.
]]></description>
<dc:creator><![CDATA[ Merriwether, E. N., Maqsood, M. N., Vanegas, S. M., Em, S., Perez, N., Parikh, M., Ruiz-Guerenabarrena, B., Humala-Martinez, C., Lopez, B., Fillingim, R. B., Jay, M. ]]></dc:creator>
<dc:date>2026-08-06</dc:date>
<dc:identifier>doi:10.64898/2026.08.04.26359660</dc:identifier>
<dc:title><![CDATA[Biobehavioral pain profiling of minoritized adults with chronic widespread pain and clinical obesity before and after bariatric surgery: study protocol for a longitudinal, observational cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.08.03.26359604v1?rss=1">
<title>
<![CDATA[
Multidimensional symptom burden across sleep, pain, affect, cognition and energy: cross-sectional associations with chronic pain interference and work disability in UK Biobank 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.08.03.26359604v1?rss=1
</link>
<description><![CDATA[
BackgroundSleep, pain, affect, cognition and energy (SPACE) has been described as a latent symptom-severity construct in chronic overlapping pain conditions. Its population-level structure and associations with chronic pain interference and functional disability remain uncertain.

MethodsWe conducted a cross-sectional analysis of UK Biobank participants aged [&ge;]40 years. Prespecified standardised symptom domains were examined using correlation analysis, principal component analysis, exploratory factor analysis and k-means clustering. Associations with chronic pain interference, current work disability, poor self-rated health and longstanding illness or disability were assessed using covariate-adjusted logistic regression. A four-domain score excluding pain tested whether associations extended beyond the pain domain. Secondary analyses examined convergence with actigraphy, biomarkers, polygenic risk scores and brain magnetic resonance imaging phenotypes.

ResultsOf 501,935 eligible participants, 475,134 had complete domain data. Domains were modestly intercorrelated (r=0.04-0.46). Clustering identified lower- and higher-burden phenotypes comprising 70.5% and 29.5% of participants; current work disability occurred in 1.3% and 10.3%, respectively. Adding the four non-pain domains increased the area under the curve for chronic pain interference from 0.593 to 0.672 and for work disability from 0.748 to 0.850. Inclusion of pain increased the work-disability area under the curve to 0.863. Multimodal measures added smaller increments.

ConclusionsA multidimensional symptom profile was identifiable at population scale and was concurrently associated with chronic pain interference and work disability, with non-pain domains contributing information beyond pain burden alone.

SignificanceChronic pain interference and work disability were associated with a broader multidimensional symptom burden spanning sleep, affect, cognition and energy, rather than pain alone. In a large population cohort, the non-pain domains added substantial concurrent discriminatory information. These findings support multidimensional assessment of functionally impairing pain and justify prospective evaluation of whether symptom-system profiles predict incident disability, healthcare use, recovery trajectories or treatment response.
]]></description>
<dc:creator><![CDATA[ Ciechanowicz, S., Li, K., Ma, D. ]]></dc:creator>
<dc:date>2026-08-05</dc:date>
<dc:identifier>doi:10.64898/2026.08.03.26359604</dc:identifier>
<dc:title><![CDATA[Multidimensional symptom burden across sleep, pain, affect, cognition and energy: cross-sectional associations with chronic pain interference and work disability in UK Biobank]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.31.26359372v1?rss=1">
<title>
<![CDATA[
Pain-Reporting Variability and Reliability as Predictors of Placebo Effects: A Cross-Sectional Experimental Pain Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.31.26359372v1?rss=1
</link>
<description><![CDATA[
Placebo analgesia varies substantially across individuals, yet the sources of this heterogeneity remain incompletely understood. Pain-reporting variability may represent an underrecognized predictor of placebo responsiveness. This study examined whether variability and reliability of pain reporting predict placebo analgesia in an experimental pain setting.

Eight hundred and three participants (401 individuals with temporomandibular disorder and 400 healthy controls) completed a standardized thermal pain paradigm involving calibration, placebo conditioning, and testing phases. We obtained repeated heat temperatures (four) during thermal calibration and pain ratings during conditioning test (24 trials). We used these measurements to quantify within-person pain-reporting variability using standard deviation (SD) and coefficient of variation (CoV), and reliability using intraclass correlation coefficients (ICC). Placebo analgesia was calculated as the difference in pain ratings between control and placebo cue trials during testing. Regression models examined associations between reporter characteristics and placebo analgesia controlling for age, sex, race and experimenters.

Variability of thermal pain responses during calibration did not predict placebo analgesia. Greater pain-reporting variability during conditioning was associated with reduced placebo analgesia (higher SD and CoV), and this effect was mediated by slower acquisition of the cue- pain contingency. Conditioning-phase reliability was not associated with placebo analgesia, whereas three clusters of learning profiles predicted placebo effects. Thus, individual differences in pain-reporting variability during conditioning, rather than baseline sensory variability, contribute to heterogeneity in placebo analgesia. These findings suggest that variability during acquisition processing matters more than general sensory variability influencing the magnitude of placebo effects.
]]></description>
<dc:creator><![CDATA[ Cottam, J. A. R., Wang, Y., Akintola, T., Farrar, J., Chen, C., McArdle, P., Ament, S. A., Corlett, P. A., Dorsey, S. G., Treister, R., Colloca, L. ]]></dc:creator>
<dc:date>2026-08-03</dc:date>
<dc:identifier>doi:10.64898/2026.07.31.26359372</dc:identifier>
<dc:title><![CDATA[Pain-Reporting Variability and Reliability as Predictors of Placebo Effects: A Cross-Sectional Experimental Pain Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.24.26357716v1?rss=1">
<title>
<![CDATA[
Analgesic Efficacy of Native Himalayan Shilajit as Add-On Therapy in Myofascial Pain Syndrome: An Exploratory Pilot Clinical Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.24.26357716v1?rss=1
</link>
<description><![CDATA[
BACKGROUNDMyofascial Pain Syndrome (MPS) is a common musculoskeletal pain condition associated with myofascial trigger points that has been reported to occur in 30-93% of patients who present with musculoskeletal pain. The current pharmacologic treatments (such as nonsteroidal anti-inflammatory drugs [NSAIDs], muscle relaxants, and tricyclic antidepressants) are only partially effective and have side effects. Shilajit, a mineral-organic exudate from the Himalayas, has antioxidant, anti-inflammatory, mitochondrial bioenergetic, and central analgesic effects and has not previously been examined as an analgesic in any musculoskeletal pain condition.

METHODSThis was an exploratory pilot clinical trial with open-label design in a single arm for an 18-month period at All India Institute of Medical Sciences (AIIMS), Rishikesh, India. Patients aged 18 to 65 years with clinically diagnosed MPS (Simons et al. 1999 criteria) and a baseline visual analog scale (VAS) score >4 were enrolled. Native Himalayan Shilajit 250 mg daily was administered as add-on therapy for 49 days. The main outcome was the percentage of participants with [&ge;]30% VAS reduction at Day 49. The intensity of pain, the dose of analgesics consumed and the number of trigger points were evaluated at five time points (Day 0, 12, 24, 36, 49). Throughout, adverse events were monitored.

RESULTSOf 80 enrolled participants, 76 (95.0%) completed the per-protocol analysis. Mean age was 41.25 {+/-} 9.05 years; 52.6% were male. A total of 56 of 76 participants (73.7%; 95% CI: 62.1- 82.8%) achieved the primary endpoint. Mean VAS score declined from 6.63 {+/-} 1.08 at baseline to.63 {+/-} 1.72 at Day 49 (mean reduction 45.3%; Friedman {chi}2 = 278.5, p<0.001). The first signs of pain reduction were seen at Day 24. The number of analgesic doses consumed decreased by 75.5% during the study period ({chi}2 = 126.1, p<0.001). There was a significant reduction in trigger point count from baseline to Day 49 (p=0.031) of 23.4%. One Grade 2 adverse event (gastrointestinal irritation, Day 28, resolved within 24 hours, no drug discontinuation) occurred; no serious adverse events were reported. Trial registration: CTRI/2025/06/088636. The study was not funded by any external sources.

CONCLUSIONSNative Himalayan Shilajit 250 mg/day for 49 days was associated with clinically and statistically significant reductions in pain intensity, analgesic consumption, and trigger-point burden in patients with MPS, with a favorable safety profile. These findings warrant confirmation in a larger, randomized, placebo-controlled trial.
]]></description>
<dc:creator><![CDATA[ Basavaraja, D., Kant, R., Pai, V. S., Yadav, R., Chikara, G., Tomar, S., Sircar, D., Sambhaji, K. R., Panda, P. K. ]]></dc:creator>
<dc:date>2026-08-03</dc:date>
<dc:identifier>doi:10.64898/2026.07.24.26357716</dc:identifier>
<dc:title><![CDATA[Analgesic Efficacy of Native Himalayan Shilajit as Add-On Therapy in Myofascial Pain Syndrome: An Exploratory Pilot Clinical Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-08-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.24.26358500v1?rss=1">
<title>
<![CDATA[
Development and Psychometric Validation of the Pelvic Dystonia Severity Scale (PDSS) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.24.26358500v1?rss=1
</link>
<description><![CDATA[
BackgroundChronic pelvic pain with involuntary pelvic-floor hypertonicity is common, disabling, and inconsistently measured, and no validated condition-specific severity instrument exists. A refractory subset has been proposed to represent a focal dystonia of the pelvic musculature, termed pelvic dystonia.

PurposeTo develop the Pelvic Dystonia Severity Scale (PDSS) and evaluate its measurement properties as a patient-reported measure of pelvic-pain symptom severity and burden, following the COSMIN guidelines.

MethodsCross-sectional study with a test-retest component in 102 adults from an outpatient multidisciplinary pain practice. We assessed data quality, structural validity, internal consistency, test-retest reliability, measurement error, and construct validity against the Global Dystonia Severity Rating Scale (GDS) and Brief Pain Inventory (BPI). Because no validated diagnostic criteria exist, a clinician blinded to PDSS responses rated each participant for clinical signs of pelvic dystonia (present/possible/absent) as a provisional reference standard.

Results100 of 102 participants (98%) returned complete data, with 0% item-level missing data. Factor analysis supported a unidimensional structure (single factor, 68.6% of variance; loadings 0.56-0.93), with high subscale intercorrelations (r = 0.81-0.97). Internal consistency (Cronbachs  0.810-0.924) and test-retest reliability (ICC 0.857-0.953) were strong. Convergent validity was supported by correlations with GDS pelvic-region items (r = 0.56-0.68) and BPI severity (r = 0.44-0.55), and discriminant validity by weak correlations with anatomically remote regions (shoulder/arm r = 0.03-0.16). PDSS scores rose monotonically across blinded clinical-signs categories (absent 14.9, possible 32.7, present 52.0; Kruskal-Wallis p < 0.001), discriminating signs-present from signs-absent participants with a very large effect (Hedges g = 2.19; ROC AUC = 0.92).

ConclusionThe PDSS is a psychometrically robust, unidimensional measure of pelvic-pain symptom severity and burden with strong data quality, reliability, and construct validity. It is suitable for characterizing symptom severity and, pending responsiveness testing, for monitoring treatment. The dystonia interpretation of the underlying phenotype is discussed as a hypothesis for future neurophysiologic and longitudinal study.
]]></description>
<dc:creator><![CDATA[ Siefferman, J., Safroshkina, M., Nazarova, I., Zaznaev, A., Hasan, S. ]]></dc:creator>
<dc:date>2026-07-27</dc:date>
<dc:identifier>doi:10.64898/2026.07.24.26358500</dc:identifier>
<dc:title><![CDATA[Development and Psychometric Validation of the Pelvic Dystonia Severity Scale (PDSS)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.22.26358710v1?rss=1">
<title>
<![CDATA[
Assessing Pain Catastrophizing Through Free-Text Responses: A Validation of Large Language Models 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.22.26358710v1?rss=1
</link>
<description><![CDATA[
Validated measures of pain catastrophizing primarily assess catastrophizing as a stable trait. However, emerging evidence suggests catastrophizing fluctuates with context, highlighting a need for ecologically valid methods to capture it. This study evaluated large language models (LLMs) as implicit markers of catastrophizing from free-text responses from ninety-one adults with chronic pain receiving long-term opioid therapy (57.3% Female; mean age = 60.5 years). Patients completed baseline measures, including the trait pain catastrophizing scale (PCS), followed by a 10-minute writing task after random assignment to a negative, positive, or neutral pain-coping condition. State affect and pain were assessed before and after writing tasks and again after a cold pressor task (4{o}C; [&le;] 2 minutes). A state PCS followed the cold pressor task. Free-text responses were analyzed using four LLMs (Claude Opus 4; GPT Mini 4o; Llama 4 Maverick; and Gemini 2.5 Pro). ANOVA-based results supported discriminant validity, as all four LLM-derived pain catastrophizing scores differentiated negative from positive and neutral pain-coping conditions. Convergent validity was model-dependent; only Gemini-derived scores correlated with state catastrophizing (r = .22) and pain unpleasantness (r = .23). Divergent validity was mixed. LLM-derived scores were unrelated to pain intensity, but Gemini and Claude-derived scores showed small correlations with trait PCS (rs = .21; 28, respectively). All LLM-derived scores also correlated with negative affect (rs = .29-.41), comparable in magnitude to state PCS, suggesting limited specificity. These findings provide preliminary evidence that certain LLMs may serve as implicit markers of state pain catastrophizing, but further study is needed.

SummaryLeading Large Language Models (LLMs) demonstrate discriminant validity but mixed convergent and divergent validity scoring pain catastrophizing from persons living with chronic pain free-text responses.
]]></description>
<dc:creator><![CDATA[ Lee, A., You, D. S., Dildine, T. C. ]]></dc:creator>
<dc:date>2026-07-24</dc:date>
<dc:identifier>doi:10.64898/2026.07.22.26358710</dc:identifier>
<dc:title><![CDATA[Assessing Pain Catastrophizing Through Free-Text Responses: A Validation of Large Language Models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.22.26358645v1?rss=1">
<title>
<![CDATA[
Palliative Care among People with Advanced Heart Failure: Between Hospital Variation in the US Veterans Administration 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.22.26358645v1?rss=1
</link>
<description><![CDATA[
BackgroundPalliative care is recommended by clinical practice guidelines for patients with advanced heart failure (aHF), yet specialty palliative care (SPC) remains substantially underutilized in this population. We sought to quantify between-facility variation in SPC receipt among people with aHF and determine how much variation is explained by patient case mix and facility structural characteristics versus residual unmeasured factors.

MethodsThis retrospective cohort study included 23,991 Veterans with prevalent aHF identified through administrative data across 133 VA Medical Centers (VAMCs) with [&ge;]20 aHF cases, from January 2022 to December 2023. Variation was assessed using multilevel logistic regression with facility random intercepts, the intraclass correlation coefficient (ICC), and the adjusted median odds ratio (aMOR). Facility-specific risk-standardized SPC rates were used to estimate SPC encounters attributable to facility performance better or worse than the national rate.

ResultsOf the sample, the mean patient age was 72.3 years (SD = 10.0), and 97.6% were male. The national observed rate of SPC was 17.5%, with risk-adjusted rates varying approximately 14-fold across facilities (3.3% to 45.6%). The adjusted ICC was 11.5%, and aMOR was 1.87 (95% Confidence Intervals 1.70-2.06). Measured patient case-mix and facility structural characteristics explained only 18.9% of between-facility variation (proportional reduction in the ICC, fully adjusted vs. null model). Facilities performing better than the national rate delivered 791 more SPC encounters than expected (17.8%), while those performing worse than the national rate delivered 480 fewer encounters than expected (10.8%).

ConclusionsIn the context of a national mean rate of SPC that reflects substantial underuse, delivery varied 14-fold across VAMCs, with most variation unexplained by patient complexity or measured facility resources. These findings suggest that potentially modifiable organizational factors, beyond patient preferences or facility structures alone, may contribute to current utilization gaps and represent actionable targets for quality improvement.

Clinical PerspectiveO_ST_ABSWhat is new?C_ST_ABSIn this national cohort of 23,991 people with advanced heart failure cared for at 133 VA Medical Centers, risk-adjusted rates of specialist palliative care delivery varied 14-fold across facilities (median odds ratio 1.87). Measured patient case-mix and facility structural characteristics explained only 18.9% of the between-facility variation.

Clinical implications?Substantial variation in palliative care delivery across VAMCs is not accounted for by differences in patient complexity or facility resources, suggesting that institutional processes and referral practices are key drivers and represent actionable targets for quality improvement.
]]></description>
<dc:creator><![CDATA[ Feder, S., Ouyang, N., Han, L., Abel, E., DeRycke, E., Kinder, D., Redeker, N., Curry, L. A., Lurhs, C., Levy, C., Ibarra, J., Kavalieratos, D., Akgun, K., Allen, L. A. ]]></dc:creator>
<dc:date>2026-07-23</dc:date>
<dc:identifier>doi:10.64898/2026.07.22.26358645</dc:identifier>
<dc:title><![CDATA[Palliative Care among People with Advanced Heart Failure: Between Hospital Variation in the US Veterans Administration]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.12.26356929v1?rss=1">
<title>
<![CDATA[
JAK-STAT pathway inhibition modulates centrally sensitised default mode network hubs in rheumatoid arthritis pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.12.26356929v1?rss=1
</link>
<description><![CDATA[
Nociplastic pain represents a major burden across immune-mediated inflammatory diseases (IMIDs). It is hypothesised, but not yet demonstrated, that peripheral inflammation promotes nociplastic pain by bottom-up sensitisation of the central nervous system (CNS). In rheumatoid arthritis (RA), a prototypic IMID, we used ultra-high field (7T) brain resting-state functional MRI to evaluate whether peripherally targeted anti-inflammatory therapies alter a biomarker of bottom-up CNS sensitisation: inferior parietal lobule (IPL)-insula connectivity. In discovery and replication cohorts, JAK-STAT pathway inhibitors significantly shifted IPL-insula connectivity toward a normalised pattern. This effect was not seen with placebo or anti-TNF therapy. Moreover, after performing an agnostic whole-brain multivariate analysis of functional connectivity change related to JAK-STAT inhibition, the posterior cingulate cortex (PCC) was identified; like the IPL, a major hub of the default mode network (DMN). We then probed the DMN with transcranial magnetic stimulation in an independent RA cohort. Active, but not sham, stimulation altered DMN connectivity and reduced peripheral blood monocyte pSTAT3 function, a surrogate of immune inactivation, suggesting a bi-directional brain-immune circuit. Together, these findings provide the first human experimental evidence that peripheral JAK-STAT pathways contribute to nociplastic pain in IMIDs.

One Sentence SummaryBlocking peripheral JAK-STAT signalling reduces both objective and subjective nociplastic pain in rheumatoid arthritis, revealing a localised inflammatory driver behind a traditionally non-inflammatory pain state.
]]></description>
<dc:creator><![CDATA[ Stefanov, K., Parkinson, J. T., Sunzini, F., Al-Wasity, S., Kaplan, C. M., Schrepf, A., Ichesco, E., Porter, D. A., Keith, G. A., McGucken, A., Brock, J., Aldehmi, N., Paramo-Fiscal, L., Tulunay-Virlan, A., Arnott, M., Lau, T., Goodyear, C., Thut, G., Shenker, N., McInnes, I. B., Clauw, D. J., Cavangh, J., Basu, N. ]]></dc:creator>
<dc:date>2026-07-14</dc:date>
<dc:identifier>doi:10.64898/2026.07.12.26356929</dc:identifier>
<dc:title><![CDATA[JAK-STAT pathway inhibition modulates centrally sensitised default mode network hubs in rheumatoid arthritis pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.11.26357570v1?rss=1">
<title>
<![CDATA[
Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.11.26357570v1?rss=1
</link>
<description><![CDATA[
BackgroundDemoralization, a syndrome of helplessness, hopelessness, and loss of meaning and chronic pain are common sources of distress in early palliative care. Psilocybin-assisted therapy (PAT) is an emerging intervention with preliminary data suggesting improvements in pain and demoralization. To date, PAT has not been studied among people living with both demoralization and chronic pain nor has it been studied as part of routine multidisciplinary outpatient palliative care.

ObjectivesWe conducted an open-label pilot study assessing the safety, feasibility, and acceptability of PAT delivered with multidisciplinary palliative care support in cancer patients across the illness trajectory living with demoralization and chronic pain.

MethodsParticipants received a single 25 mg oral dose of psilocybin with preparation, monitoring, and integration provided by a mental health clinician and spiritual health clinician, alongside multidisciplinary palliative care support. Outcomes included safety, feasibility, acceptability, and exploratory self-report measures assessing for demoralization and pain intensity pre- and post-dosing.

ResultsEleven participants were enrolled, ten of whom received psilocybin. The intervention was safe and feasible, with no serious adverse events and complete study visit retention among dosed participants. All 10 dosed participants reported the intervention as highly acceptable. Among dosed participants, 70% rated the experience among the five most meaningful and educational of their lives, and 60% among their five most spiritually significant experiences. By study endpoint, 90% no longer met criteria for clinically-significant demoralization syndrome and had pain scores below the trial enrollment threshold.

ConclusionsPAT delivered with multidisciplinary palliative care support was safe, feasible, and acceptable in demoralized cancer patients with chronic pain.

Key MessagePsilocybin-assisted therapy delivered within multidisciplinary outpatient palliative care was safe, feasible, and acceptable among demoralized cancer patients with chronic pain.
]]></description>
<dc:creator><![CDATA[ Zarrabi, A. J., Mletzko, T., Grant, G., Peacock, C., Palitsky, R. J., McPherson, T., Shub, I., Eisenacher, S., Maples-Keller, J. L., Kaplan, D., Rothbaum, B. O., Rab, F., Dalal, N., Curseen, K. A., Raison, C., Dunlop, B. W. ]]></dc:creator>
<dc:date>2026-07-14</dc:date>
<dc:identifier>doi:10.64898/2026.07.11.26357570</dc:identifier>
<dc:title><![CDATA[Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.08.26357000v1?rss=1">
<title>
<![CDATA[
Music listening for chronic pain management: a systematic review, meta-analysis, and evaluation of intervention reporting quality 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.08.26357000v1?rss=1
</link>
<description><![CDATA[
BackgroundChronic pain is a multidimensional condition that often persists despite conventional treatment and adversely affects multiple domains of daily life. Music listening has emerged as a promising non-pharmacological intervention, with accumulating evidence supporting its beneficial effects on pain and associated psychological outcomes. However, despite growing evidence of efficacy, the translation of music listening into routine clinical practice remains limited, partly because intervention reporting has received comparatively little attention.

ObjectiveTo evaluate the effectiveness of music listening interventions for chronic pain and systematically assess the methodological quality and completeness of intervention reporting to identify barriers to reproducibility and clinical implementation.

MethodsSystematic searches were conducted in PubMed, Cochrane Library, CINAHL, and Web of Science through June 2025, with no date restrictions on publication. Randomized controlled trials involving adults with chronic pain receiving music listening interventions were included. Two independent reviewers screened studies, extracted data, and assessed risk of bias. Intervention reporting was evaluated using the TIDieR checklist, and a random-effects meta-analysis was performed for pain intensity outcomes.

ResultsTen RCTs involving 538 participants were included. Music listening interventions varied substantially in delivery, duration, and music selection procedures, reflecting considerable heterogeneity in intervention design. Most studies reported significant improvements in pain and psychological outcomes. Meta-analysis of eight trials (10 effect estimates), demonstrated a moderate reduction in pain intensity (SMD = -0.53, 95% CI: -0.96 to -0.11, p = 0.014; I{superscript 2} = 76.2%). Although intervention rationale and procedures were generally well described, reporting of intervention modifications, treatment fidelity, and adherence was frequently incomplete. These reporting deficiencies may compromise reproducibility and limit translation into clinical practice.

ConclusionsMusic listening appears to be a safe, accessible, and scalable non-pharmacological intervention for chronic pain management, with benefits extending beyond pain reduction to psychological wellbeing, quality of life, and functioning. However, incomplete reporting of key intervention components may limit reproducibility and hinder clinical implementation. Future trials should adopt standardized and transparent reporting standards to facilitate implementation into clinical practice.
]]></description>
<dc:creator><![CDATA[ Garrido-Pedrosa, J., Saez, M. T., Zapata, L., Porto, M. F., Valenzuela, R., Rodriguez-Fornells, A., Fernandez-Duenas, V., Grau-Sanchez, J. ]]></dc:creator>
<dc:date>2026-07-13</dc:date>
<dc:identifier>doi:10.64898/2026.07.08.26357000</dc:identifier>
<dc:title><![CDATA[Music listening for chronic pain management: a systematic review, meta-analysis, and evaluation of intervention reporting quality]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.01.26356632v1?rss=1">
<title>
<![CDATA[
The analgesic effect of ultrasound-guided fascia hydrorelease around the artery for myofascial neck pain: a prospective single-arm interventional study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.01.26356632v1?rss=1
</link>
<description><![CDATA[
Myofascial pain syndrome (MPS) is a major cause of chronic neck pain, with tissue ischemia implicated as a contributing factor. This prospective, single-arm interventional study evaluated the analgesic effect of ultrasound-guided fascia hydrorelease (US-FHR) performed around arteries supplying the neck in patients with chronic neck MPS. Thirteen adults (median age 53.0 years; 38.5% female) underwent US-FHR targeting the perivascular fascia of either the transverse cervical or dorsal scapular artery using 2 mL of normal saline. Pain intensity was assessed by visual analog scale (VAS) at rest and during movement; disability by the 5-item Pain Disability Index, Japanese version (PDI-5-J); and arterial blood flow volume before and after the procedure. The primary outcome, pain VAS during movement, decreased from 49.0 mm (interquartile range [IQR], 44.5-64.0) at baseline to 22.0 mm (IQR, 14.5-31.5) at 15 min and 22.0 mm (IQR, 14.0-34.0) at 1 week (Hodges-Lehmann median difference, 30.5 mm [95% CI, 24.5 to 36.5] and 28.5 mm [95% CI, 18.5 to 37.0]; both P < 0.001). Pain VAS at rest improved from 21.0 mm (IQR, 13.0-43.5) to 8.0 mm at 15 min and 1 week (median difference, 14.5 mm [95% CI, 9.0 to 24.0; P = 0.001] and 13.5 mm [95% CI, 6.0 to 21.0; P = 0.007]). PDI-5-J decreased from 17.0 (IQR, 10.5-23.0) to 13.0 (IQR, 4.0-17.5) at 1 week (median difference, 5 [95% CI, 2 to 8; P = 0.004]). Blood flow volume increased from 11.2 mL/min (IQR, 4.5-14.4) to 17.2 mL/min (IQR, 6.1-23.7) immediately after US-FHR (median difference, +4.1 mL/min [95% CI, +2.5 to +8.9; P = 0.001]), although transient. One patient experienced transient bleeding that was promptly controlled. In this single-arm feasibility study, US-FHR around the target artery was simple and safe to perform and was associated with reduced neck pain. Because the study lacked a control group, these preliminary findings should be regarded as hypothesis-generating and require confirmation in controlled trials; they may also inform the future evaluation of MPS in other anatomical regions. Trial registration: UMIN Clinical Trials Registry, UMIN000053612.
]]></description>
<dc:creator><![CDATA[ Hiroki, T., Kimura, H., Kobayashi, T., Horigome, H., Suda, M., Fukui, S., Suto, T., Obata, H. ]]></dc:creator>
<dc:date>2026-07-10</dc:date>
<dc:identifier>doi:10.64898/2026.07.01.26356632</dc:identifier>
<dc:title><![CDATA[The analgesic effect of ultrasound-guided fascia hydrorelease around the artery for myofascial neck pain: a prospective single-arm interventional study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.02.26356879v1?rss=1">
<title>
<![CDATA[
Exploring stakeholder perspectives on the content, delivery, and contextual delivery of shared decision-making for people living with subacromial pain syndrome: a multimethod study with future workshops and interviews 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.02.26356879v1?rss=1
</link>
<description><![CDATA[
BackgroundShared decision-making (SDM) is a key component in patient-centered care for people consulting health care due to chronic musculoskeletal pain, including subacromial pain syndrome (SAPS). Limited research has explored how patients, relatives, and healthcare professionals perceive the content and delivery of SDM for managing SAPS in primary care. Thus, this study aims to explore stakeholder perspectives on the content, delivery, and contextual requirements for a context-specific SDM intervention for SAPS, and to identify shared challenges and co-develop ideas to inform intervention development.

MethodsWe conducted three separate future workshops (patients/relatives, physiotherapists/chiropractors, and general practitioners), each consisting of structured critique, fantasy, and implementation phases. A rapid preliminary analysis of workshop data was followed by semi-structured stakeholder interviews to validate, challenge, or elaborate the findings. All data were analysed thematically using an iterative, reflexive approach.

ResultsTwenty-eight participants took part across three workshops: patients/relatives (n = 10), physiotherapists/chiropractors (n = 12), and general practitioners (n = 6). Six additional stakeholders provided inputs via subsequent interviews (three physiotherapists, one patient, one relative and one GP). Thematic analysis identified 20 themes and 59 sub-themes, which were refined into two overarching categories: (1) shared barriers to SDM in SAPS care, including diagnostic uncertainty, fragmented clinical care pathways, time constraints, and decision fatigue; and (2) stakeholder visions for future SDM interventions, emphasising continuity, tailored communication tools, and supportive digital ecosystems.

ConclusionBased on stakeholder input, SDM in SAPS care may consider integrating dynamic, integrated systems that account for diagnostic ambiguity, contextual constraints, and varying patient capacities. These findings provide an actionable foundation for co-developing and piloting a context specific SDM intervention for primary care.
]]></description>
<dc:creator><![CDATA[ Lyng, K. D., Johansen, S. K., Foster, N. E., Olesen, J. L., Thomsen, J. L., Soendergaard, J., Rathleff, M. S. ]]></dc:creator>
<dc:date>2026-07-10</dc:date>
<dc:identifier>doi:10.64898/2026.07.02.26356879</dc:identifier>
<dc:title><![CDATA[Exploring stakeholder perspectives on the content, delivery, and contextual delivery of shared decision-making for people living with subacromial pain syndrome: a multimethod study with future workshops and interviews]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.01.26356998v1?rss=1">
<title>
<![CDATA[
Improving palliative care for babies, children, young people and adults from ethnically diverse communities: a qualitative multiple case study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.01.26356998v1?rss=1
</link>
<description><![CDATA[
BackgroundPalliative care services appear less able to reach people from ethnically diverse communities and if they do, people from these communities report having different and often poorer experiences. The barriers to access are well described so research investigating potential solutions is needed.

AimsTo understand how improved palliative care outcomes for people from ethnically diverse communities have or could be achieved, and what contextual issues have influenced these outcomes.

MethodsQualitative multiple case study. The cases were defined as areas across England with services providing generalist or specialist palliative care to adults and/or children. Interviews were conducted with patients, family carers, parents (from ethnically diverse communities), health and social care professionals. Data were analysed using thematic framework analysis.

FindingsCases (n=6) included 71 participants. Five solution focused themes were identified; how the conditions for culturally and spiritually safe care are created; engagement and trust building between ethnically diverse communities and the providers that serve them as a mechanism to promote access; workforce composition and diversity helping to bridge the gap between ethnically diverse communities and services; how communication practices enable equitable care for people who have English as an additional language and organisational commitment and partnership as drivers of sustainable change.

ConclusionsEquitable access to quality palliative care is not a marginal policy issue with the economic and moral argument for change strong. Care systems need to recognise, partner with, and build upon existing community strengths. Change requires intent, accountability, leadership and the reallocation of attention and responsibility.

HighlightsO_LIEnvironmental changes and flexible care enable people to feel safe and respected.
C_LIO_LIUsing an asset-based community engagement approach is useful to improve access.
C_LIO_LILocal staff can bridge the gap between services and ethnically diverse communities.
C_LIO_LIAccess to interpreters and translated material is imperative for equitable care.
C_LIO_LISustainable change requires organisational commitment and partnership working.
C_LI
]]></description>
<dc:creator><![CDATA[ Dunleavy, L., Gould, S., Clarke, G., Cotterell, N., Bajwah, S., Evans, C., Fraser, L., Mitchell, S., Preston, N., Walshe, C. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.07.01.26356998</dc:identifier>
<dc:title><![CDATA[Improving palliative care for babies, children, young people and adults from ethnically diverse communities: a qualitative multiple case study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.15.26355697v1?rss=1">
<title>
<![CDATA[
Pain Catastrophizing, Pain Self-Efficacy, and their Interaction as Predictors of Health  Outcomes in Chronic Pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.15.26355697v1?rss=1
</link>
<description><![CDATA[
IntroductionPain catastrophizing and pain self-efficacy are well-established predictors of health outcomes in chronic pain. Higher pain catastrophizing, a maladaptive cognitive process, predicts worse health outcomes, whereas higher pain self-efficacy, an adaptive cognitive process, predicts better health outcomes. This study examined whether pain catastrophizing and pain self-efficacy interactions predict physical and psychosocial health outcomes at 3 months and their change over 3-months among patients with chronic pain who sought care at a tertiary pain clinic.

MethodsAdults with chronic pain (N = 181; 66.7% female; Mage = 58.7) completed baseline assessments of the Pain Catastrophizing Scale (PCS), Chronic Pain Self-Efficacy Scale (CPSS), and PROMIS measures of physical (pain intensity, pain interference, physical function) and psychosocial health (depression, anxiety, anger, loneliness). PROMIS measures were repeated at 3 months. Hierarchical multiple regression analyses tested PCS, CPSS, and their interaction as predictors of outcomes at 3 months and change scores from baseline to 3 months.

ResultsThe PCSxCPSS interaction significantly improved prediction for physical function ({Delta}R2 = 0.02, p = .02). Higher baseline self-efficacy predicted better physical function ({beta} = 0.65, p < .001), but this effect weakened with higher levels of pain catastrophizing. The interaction also predicted change scores in physical function (p = .025) but was marginal after false discovery rate correction (p = .059). Additionally, a significant interaction emerged for loneliness change scores (p = .01): higher self-efficacy predicted greater reductions in loneliness, attenuated by higher catastrophizing.

ConclusionPain self-efficacy interacted with pain catastrophizing to predict physical function and loneliness at 3 months. Greater self-efficacy was associated with better outcomes, with associations diminished with higher levels of pain catastrophizing. Findings highlight the moderating role of adaptive and maladaptive cognitions and suggest interventions should address both processes to optimize recovery in physical and social functioning.

Key MessageAn interaction between pain catastrophizing and pain self-efficacy predicted physical function and changes in loneliness at 3 months. Greater self-efficacy was associated with better physical function and greater decreases in loneliness, but these associations weakened as catastrophizing increased. These findings highlight how maladaptive and adaptive pain-related cognitions interacted to predict physical and social function in chronic pain.
]]></description>
<dc:creator><![CDATA[ Raney, E. M., Dildine, T. C., Kim, S., Mackey, S. C., You, D. S. ]]></dc:creator>
<dc:date>2026-06-26</dc:date>
<dc:identifier>doi:10.64898/2026.06.15.26355697</dc:identifier>
<dc:title><![CDATA[Pain Catastrophizing, Pain Self-Efficacy, and their Interaction as Predictors of Health  Outcomes in Chronic Pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.23.26356401v1?rss=1">
<title>
<![CDATA[
Fairness-aware, explainable clinical decision support for opioid use disorder risk stratification: development and internal validation of a dual-layer AI system 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.23.26356401v1?rss=1
</link>
<description><![CDATA[
Opioid use disorder (OUD) remains a leading cause of preventable death in the United States, yet the tools used to assess OUD risk rely on episodic self-report, produce binary output, and exhibit documented performance disparities across demographic groups that can widen existing inequities in care. Machine-learning models for OUD risk are seldom evaluated for demographic fairness or designed for the transparency clinicians need to trust and act on them. We present a fairness-aware, explainable clinical decision support system for four-tier OUD risk stratification, developed and internally validated on a large electronic health record-derived cohort accessed via Mayo Clinic Platform_Discover. The system pairs an XGBoost classifier with a transparent Clinical Rules Engine that attributes risk across six clinical domains, providing clinician-interpretable explanations alongside each prediction. To address demographic disparity directly, we applied an iterative bias-mitigation strategy combining age-balanced resampling, removal of race as a model input, and cost-sensitive reweighting, and measured its effect using group-fairness metrics (demographic parity, equal opportunity, equalized odds, and calibration within groups). On a held-out internal test set, mitigation reduced the White-Black gap in high-risk detection from 30.3 to 7.4 percentage points (a 76% relative reduction) and the age-based accuracy gap from 6.6 to 2.7 percentage points (59% reduction), raising high-risk detection for Black patients from 58.3% to 75.0%, at a cost of fewer than two percentage points of overall accuracy; gender differences remained below three points. The system was independently qualified through Mayo Clinic Platform_Solutions Studio. This work offers an implementable, transparent blueprint for operationalizing fairness and explainability in clinical AI for high-risk prescribing, with external and prospective validation as the clear next steps.
]]></description>
<dc:creator><![CDATA[ Kazgan, M., Mohammadvand, N., Cetin, B. ]]></dc:creator>
<dc:date>2026-06-26</dc:date>
<dc:identifier>doi:10.64898/2026.06.23.26356401</dc:identifier>
<dc:title><![CDATA[Fairness-aware, explainable clinical decision support for opioid use disorder risk stratification: development and internal validation of a dual-layer AI system]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.21.26356167v1?rss=1">
<title>
<![CDATA[
Associations Among Changes in Inflammatory Biomarkers, Pain Intensity, and Health-Related Quality of Life Following a 12-Week Aerobic Exercise Programme in Individuals with Non-Specific Chronic Low Back Pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.21.26356167v1?rss=1
</link>
<description><![CDATA[
BackgroundNon-specific chronic low back pain (NSCLBP) is associated with persistent pain, reduced health-related quality of life (HRQoL), and low-grade systemic inflammation. This study examined associations among changes in inflammatory biomarkers, pain intensity, and HRQoL following a 12-week aerobic exercise programme.

MethodsThis secondary analysis used data from a randomized controlled trial involving 41 participants with NSCLBP (intervention, n = 21; control, n = 20). Participants received either supervised aerobic exercise plus health education or health education alone for 12 weeks. Change scores for tumour necrosis factor-alpha (TNF-), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), pain intensity, and HRQoL domains were analysed using correlation and multiple regression analyses.

ResultsImprovements in IL-6 (r = 0.434, p = 0.005) and hs-CRP (r = 0.444, p = 0.004) were significantly associated with improvements in pain intensity. No significant associations were observed between biomarker changes and HRQoL domains. Treatment allocation was the strongest independent predictor of improvement in physical HRQoL ({beta} = 0.492, p = 0.017) and pain intensity ({beta} = -0.512, p = 0.006).

ConclusionsImprovements in IL-6 and hs-CRP were associated with reductions in pain intensity but not with improvements in HRQoL. Treatment allocation was the strongest predictor of clinical improvement, suggesting that mechanisms beyond systemic inflammation may contribute to the benefits of aerobic exercise in NSCLBP.

Plain Language SummaryNon-specific chronic low back pain (NSCLBP) is a common condition that can cause persistent pain, reduce daily functioning, and negatively affect quality of life. Research suggests that low-grade inflammation may contribute to pain persistence, but it remains unclear how changes in inflammation relate to improvements in pain and health-related quality of life (HRQoL) following exercise-based rehabilitation.

This study examined the relationships among changes in inflammatory biomarkers, pain intensity, and HRQoL following a 12-week aerobic exercise programme in people with NSCLBP. Forty-one participants completed either a supervised aerobic exercise programme combined with health education or health education alone. Changes in inflammatory biomarkers (IL-6, hs-CRP, and TNF-), pain intensity, and HRQoL were assessed over the intervention period.

The findings showed that improvements in IL-6 and hs-CRP were associated with reductions in pain intensity. However, changes in inflammatory biomarkers were not significantly associated with improvements in HRQoL. The strongest predictor of improvements in both pain and physical HRQoL was participation in the aerobic exercise programme.

These findings suggest that aerobic exercise can improve outcomes in people with NSCLBP, but the benefits may not be explained solely by reductions in inflammation. Other factors, including physical, psychological, and behavioural changes associated with exercise, may also contribute to recovery and improved well-being.
]]></description>
<dc:creator><![CDATA[ Nweke, V. C., Fatai, K. E., Madume, A. K., Ojukwu, C. P., Onyekwelu, A. I., Nwosu, A. O., Nweke, Q. k., Nweke, A. C., Ezema, C. I. ]]></dc:creator>
<dc:date>2026-06-23</dc:date>
<dc:identifier>doi:10.64898/2026.06.21.26356167</dc:identifier>
<dc:title><![CDATA[Associations Among Changes in Inflammatory Biomarkers, Pain Intensity, and Health-Related Quality of Life Following a 12-Week Aerobic Exercise Programme in Individuals with Non-Specific Chronic Low Back Pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-23</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
